Gilead Sciences Inc
(GILD)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2011 | 09-2011 | 06-2011 | 03-2011 | 12-2010 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 9,883,777 | 909,359 | 905,779 | 1,835,978 | 907,879 |
| Marketable Securities | 16,491 | 1,347,776 | 1,364,539 | 1,175,321 | 1,190,789 |
| Receivables | 1,951,167 | 1,867,092 | 1,938,645 | 1,801,212 | 1,621,966 |
| Inventories | 1,389,983 | 1,337,751 | 1,321,615 | 1,304,457 | 1,203,809 |
| Income taxes - deferred | 208,155 | 283,856 | 277,611 | 277,835 | 279,339 |
| Other current assets | 5 | 115,643 | 85,018 | 96,081 | 116,244 |
| TOTAL | $13,918,790 | $6,147,267 | $6,219,045 | $6,851,132 | $5,708,082 |
| Non-Current Assets | |||||
| PPE Net | 774,406 | 761,190 | 721,884 | 703,794 | 701,235 |
| Investments And Advances | 63,704 | 3,224,981 | 3,228,994 | 3,344,999 | 3,219,403 |
| Intangibles | 2,066,966 | 2,111,003 | 2,128,410 | 1,629,971 | 1,425,592 |
| Other Non-Current Assets | 479,273 | 395,457 | 395,807 | 457,458 | 538,318 |
| TOTAL | $3,384,349 | $6,492,631 | $6,475,095 | $6,136,222 | $5,884,548 |
| Total Assets | $17,303,130 | $12,639,900 | $12,694,140 | $12,987,350 | $11,592,630 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,572 | 1,587 | 7,345 | 653,093 | N/A |
| Accounts payable and accrued liabilities | 1,206,052 | 1,063,723 | 1,102,319 | 981,631 | 803,025 |
| Accrued Expenses | 720,789 | 561,464 | 514,273 | 467,638 | 472,650 |
| TOTAL | $2,514,790 | $2,224,431 | $2,310,841 | $2,768,765 | $2,464,950 |
| Non-Current Liabilities | |||||
| Long Term Debt | 7,753,470 | 4,030,532 | 4,027,237 | 3,899,928 | 2,865,974 |
| Deferred Revenues | 74,665 | 68,673 | 63,243 | 97,373 | 103,175 |
| Other Non-Current Liabilities | 139,041 | 120,611 | 120,793 | 116,863 | 110,079 |
| TOTAL | $7,920,995 | $4,182,261 | $4,171,968 | $4,043,228 | $3,005,843 |
| Total Liabilities | $10,435,780 | $6,406,692 | $6,482,809 | $6,811,993 | $5,470,793 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,514,631 | 1,502,278 | 1,542,910 | 1,574,109 | 1,590,529 |
| Common Shares | 753 | 757 | 777 | 791 | 802 |
| Retained earnings | 1,776,760 | 1,321,796 | 1,395,908 | 1,320,335 | 1,183,730 |
| Other shareholders' equity | 186,693 | 100,901 | 31,207 | 127,926 | 289,019 |
| TOTAL | $6,867,349 | $6,233,206 | $6,211,331 | $6,175,361 | $6,121,837 |
| Total Liabilities And Equity | $17,303,129 | $12,639,898 | $12,694,140 | $12,987,354 | $11,592,630 |